Key points are not available for this paper at this time.
Alzheimer’s disease (AD) is devastating and progressive disease. The non-invasive detection of early onset AD along with the mechanisms that drive its progression are still limited. Recent work has implicated metabolic reprogramming as an earlier AD potential indicator. Therefore, we investigated an AD mouse model at the early stage of development with the goal to evaluate whether co-hyperpolarized 1-13Cpyruvate and 1-13Cdehydroascorbate (DHA) along with 3D MRSI might provide insights into the brain metabolism of FAD mice at the onset of the disease. The metabolism of these translatable biomarkers would then give insight on our understanding of AD diagnosis and treatment.
Porcari et al. (Wed,) studied this question.